Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home INVESTOR RELATIONS events & Presentations

Events & Presentations

 

ABLYNX PRESENTED AT THE 5TH ANNUAL PIPER JAFFRAY EUROPE HEALTHCARE CONFERENCE on 22 june 2010 london (UK)

     

Click here to replay the audio webcast

   

ABLYNx's FULL YEAR RESULTS 2009

     

Click here to replay the audio webcast

 

PRESENTATION IN PDF FORMAT


USA R&D Investor update

12 february 2010 - New York (ny), USA

Ablynx presented an update of its therapeutic pipeline and its recent technology advances

Friday, 12 february 2010  at 08:00 am est / 02:00 pm CET

PRESENTATION IN PDF FORMAT


28th annual jp morgan healthcare conference

11-14 January 2010 - San Francisco (CA), US

Ablynx presented at JP Morgan Healthcare Conference

Wednesday, 13 January 2010  at 11:00 am PST / 8:00 pm CET

PRESENTATION IN PDF FORMAT


51st ASH Annual Meeting and Exposition

5-8 december 2009 - NEW orleans, USA

     

Ablynx presented poster at THE 51ST ASH ANNUAL MEETING AND EXPOSITION sATURDAY, 5 december at 05.00 P.M. CST / 12.00 P.M. CET

 

poster


 

 

Latest News


27/07/2010

ABLYNX ANNOUNCES CHANGE IN MANAGEMENT

23/07/2010

ABLYNX ANNOUNCES WARRANT EXERCISE

12/07/2010

NOVARTIS OBTAINS LICENSES TO DEVELOP AND COMMERCIALISE TWO NOVEL NANOBODIES®


Email alerts

If you would like to receive updates on the company news, please
click here